Clinical Trials
15 trialsNCT05260203 2024-11-06
MargheRITA
Advice Pharma Group srl
Phase NA Completed
NCT03886831 2023-03-28
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT01241500 2020-06-30
ONTIME
Traws Pharma, Inc.
Phase 3 Completed
NCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT01295710 2019-04-09
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech
Phase 3 Completed
NCT01175785 2019-03-05
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics, Inc.
Phase 2 Completed
NCT01110473 2017-11-20
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie
Phase 1 Completed
NCT01297543 2016-07-01
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
Phase 1/2 Completed
NCT01461538 2016-03-04
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen Inc.
Phase 2 Completed
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT00592046 2012-07-19
A Phase I Trial of ZIO-101 in Hematologic Cancers
Alaunos Therapeutics
Phase 1 Completed
NCT00004047 2012-05-16
Chemotherapy in Treating Patients Who Have Hematologic Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00677859 2012-01-05
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Healios K.K.
Phase 1 Completed
NCT00195533 2009-11-16
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Completed
NCT00506402 2009-05-05
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
CASI pharmaceuticals, Inc.
Phase 1 Completed